Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AVBP with free AI briefings, catalyst countdowns, and dilution alerts.

AVBP · ArriVent BioPharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$393.2M Cash on Hand
29.4mo Cash Runway
Follow AVBP by email Get an email when AVBP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AVBP, unsubscribe in one click. Privacy

📣 What AVBP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
EGFR-TKI inhibitor based on investigator's… Non-Small-Cell Lung Cancer Phase 3 · NCT07185997 Recruiting
Firmonertinib NSCLC Phase 3 · NCT07010419 Recruiting
platinum-based chemotherapy Metastatic Non-Small Cell Lung Cancer Phase 3 · NCT05607550 Active not recruiting
ARR-002 Ovarian Cancer Phase 1 · NCT07755436 Recruiting
Anti-CDH17/Exatecan Antibody-drug Conjugate… Locally Advanced or Metastatic Solid Tumors Phase 1 · NCT07066657 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AVBP holds $393.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $40.1M/quarter from operations, an estimated runway of 29.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AVBP files for a raise →

👥 Who Owns AVBP

Insiders 19% Other 5%+ holders 4.8% Institutions (215 holders) 76.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
INFINITUM ASSET MANAGEMENT, LLC Institution (13G, 5%+) 4,123,923 7.97% 2025-12-31
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
10% owner
Insider 3,929,117 7.60% 2025-12-31
BlackRock, Inc. Institution (13G, 5%+) 3,182,080 6.15% 2026-06-30
ORBIMED ADVISORS LLC
Director, 10% owner
Includes shares also reported by Carl L Gordon, counted once
Insider 2,875,962 5.56% 2026-10-06
FMR LLC Institution (13G, 5%+) 2,863,340 5.54% 2026-09-30
Vivo Opportunity, LLC 5%+ holder (13G) 2,472,701 4.78% 2026-10-06
James Healy
Director
Insider 1,696,752 3.28% 2024-01-30
Carl L Gordon
Director, 10% owner
Insider 1,513,664 2.93% 2024-01-30
Zhengbin Yao
President and CEO, Director · +930,000 options
Insider 613,138 1.19% 2024-01-25
Robin LaChapelle
Chief Operating Officer · +373,539 options
Insider 570,906 1.10% 2026-10-30
Stuart Lutzker
President of R&D, Director · +270,000 options
Insider 147,744 0.29% 2024-01-25

Share count 51,723,074 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AVBP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVBP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.